Adicet Bio Business Summary

Adicet Bio, Inc. (ACET) is a clinical-stage biotechnology company that operates primarily through the discovery and development of allogeneic gamma delta T cell therapies. As a pre-revenue entity, the company sustains operations through strategic collaboration agreements, such as its partnership with Regeneron Pharmaceuticals, and capital market activities, including a significant $74.8 million equity offering in late 2025. Its business segments are concentrated on two therapeutic pillars: autoimmune diseases, led by its prulacabtagene leucel (prula-cel) program for lupus nephritis and systemic lupus erythematosus, and oncology, featuring the ADI-212 candidate for solid tumors like metastatic castration-resistant prostate cancer. Adicet competes directly with allogeneic cell therapy developers such as Fate Therapeutics, Kite Pharma (Gilead), and Adaptimmune Therapeutics, distinguishing itself by leveraging the unique innate and adaptive immune properties of Vδ1 gamma delta T cells to provide "off-the-shelf" treatments with enhanced tissue targeting. The company was founded by Dr. Aya Jakobovits, a renowned biotechnology pioneer who previously served as CEO of Agensys and was instrumental in the $2.2 billion acquisition of Abgenix by Amgen. Adicet is currently led by President and CEO Chen Schor, a veteran executive with over 25 years of experience who has managed strategic transactions exceeding $8 billion with firms like Pfizer and GSK. The executive suite is further anchored by Chief Technology Officer Dr. Don Healey, an expert in cell therapy manufacturing with two decades of industry experience, and Chief Scientific Officer Dr. Blake Aftab. Adicet maintains a high-pedigree investor base including OrbiMed, RA Capital Management, and BlackRock, while its board of directors features prominent industry figures such as Dr. Carl Gordon and Dr. Bastiano Sanna.